Evidence map›Paper›PMID 42004955›Full record

ArticleFrontiers in immunology2026

Ferroptosis inhibition and AMPK activation: key mechanisms of soy isoflavones against cerebral injury.

Cailian Wu, Tiantian Luo, Jinfeng Huang, Ruikang Mo

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cailian WuDepartment of Emergency, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Tiantian LuoMental Health Center, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Jinfeng HuangDepartment of Rehabilitation, The First People's Hospital of Nanning, Nanning, Guangxi, China.
Ruikang MoDepartment of Neurology, The First People's Hospital of Nanning, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cerebral ischemia-reperfusion injury (CIRI) remains a major cause of neurological disability and lacks effective neuroprotective interventions. Soy isoflavones (SI), phytoestrogens with antioxidant and anti-inflammatory properties, have shown neuroprotective potential. Given that ferroptosis contributes to CIRI pathogenesis and AMP-activated protein kinase (AMPK) regulates redox homeostasis, iron metabolism, and lipid peroxidation, we investigated whether SI protect against CIRI by activating AMPK and inhibiting ferroptosis. Methods: Male Sprague-Dawley rats subjected to middle cerebral artery occlusion (MCAO) were pretreated with SI (120 mg/kg, gavage) for 21 days. Neurological outcomes were assessed by infarct volume (TTC), brain water content, and behavioral scoring (Longa, mNSS). Ferroptosis was evaluated via cerebral Fe² Results: SI pretreatment significantly reduced infarct size, alleviated edema, and improved neurological function. SI attenuated cerebral iron accumulation, suppressed ROS and MDA production, and enhanced GSH and SOD activities. Western blot analysis revealed downregulation of ACSL4 and upregulation of GPX4, ACSL3, xCT, and ferritin, consistent with ferroptosis suppression. The protective effects of SI were abolished by RSL3, confirming ferroptosis dependence. Furthermore, MCAO suppressed AMPK activation, which was restored by SI; inhibition of AMPK with compound C intensified ferroptotic injury and negated SI's benefits, whereas co-treatment with SI reversed these detrimental effects. Conclusion: SI confer neuroprotection against CIRI by activating AMPK signaling and inhibiting ferroptosis. These findings highlight the AMPK-ferroptosis axis as a promising therapeutic target for ischemic stroke.

Indexed as

AMP-Activated Protein KinasesBrain InjuriesFerroptosisGlycine maxIsoflavonesNeuroprotective AgentsReperfusion InjuryAnimalsDisease Models, AnimalEnzyme ActivationInfarction, Middle Cerebral ArteryMaleOxidative StressRatsRats, Sprague-DawleyAMP-Activated Protein KinasesIsoflavonesNeuroprotective AgentsAMPK signaling pathwaycerebral ischemia-reperfusion injuryferroptosisMCAOsoy isoflavones

Identifiers

PMID42004955
PMCPMC13082995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.